ClinicalTrials.gg
RecruitingNCT06819865ANTEATERUpdated Oct 26, 2026

A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism

An observational study in Acute Pulmonary Embolism, sponsored by Boston Scientific Corporation. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Boston Scientific Corporation · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 26, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Pulmonary Embolism with a site in China — 26 open to participants now, 31 under way, 1 of them phase 3. Pulmonary Embolism · China.

Planned enrollment
38th of 39
30 · median 1,000
Started
2026
with 6 others
Observational
39 of 72
20 open now
Primary completion
2028-05
later than 24 of 30 live
Registered
61st of 72
by date

Among the 72 studies in Pulmonary Embolism with a site in China, this one is the 38th largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2026, is one of 39 observational ones, reaches primary completion later than 24 of the 30 other live ones, and was the 61st registered.

Pulmonary Embolism

832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

26 of the 72 studies in Pulmonary Embolism with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Pulmonary Embolism with a site in China, or all of them as a file.
02

Study summary

This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

Read the detailed description

This is a multi-center, single arm, prospective, observational, real-world study.To collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

Up to 30 patients will be enrolled in this study and up to 30 patients will be enrolled in this study to observation safety and efficacy.

03

Conditions studied

  • Acute Pulmonary Embolism

Browse trials for

Keywords

  • PE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

This study will enroll patients who received EkoSonicTM Endovascular System treatment with r-tPA for acute pulmonary thromboembolism, and who could provide sufficient echocardiographic quality to assess the collection of primary endpoint, and prospectively collect the clinical data related to the protocol in the actual clinical diagnosis and treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days).
  2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
  3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.

Exclusion criteria

Exclusion Criteria:

  1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days).
  2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
  3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Single group observational study

    To collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

    Device: EkoSonicTM Endovascular System

Interventions

  • DeviceEkoSonicTM Endovascular System

    EkoSonicTM Endovascular System and its upgraded versions if applicable The EkoSonicTM Endovascular System is a non-implanted system comprising a sterile, single-use EkoSonic Endovascular Device (Infusion Catheter and Ultrasonic Core) and reusable EKOSTM Control System 4.0(Control Unit, Connector Interface Cable and power cord).

06

What researchers measure

Primary outcomes

  1. RV vs LV end-diastolic diameter ratio

    The change in the right ventricular end-diastolic diameter to left ventricle end-diastolic diameter ratio at 48hours after the completion of EKOS treatment compared with the baseline.

    Time frame: after the completion of EKOS treatment 48 hours compared with the baseline

Secondary outcomes

  1. RV vs LV end-diastolic diameter ratio

    The change in the right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio at 24h, Discharge(Approximately within 15 days after completed treatment) , after the completion of EKOS treatment Month 1, Month 3, Month 6, compared to the baseline.

    Time frame: after the completion of EKOS treatment 24 hours, Discharge(Approximately within 15 days after completed treatment) , after the completion of EKOS treatment Month 1, Month 3, Month 6, compared to the baseline,through study completion, an average of 1 year

  2. PE events after the completion of EKOS treatment

    Recurrent symptomatic PE events after the completion of EKOS treatment.

    Time frame: After the completion of EKOS treatment 24hours, 48hours,Discharge(Approximately within 15 days after completed treatment), after the completion of EKOS treatment Month 1, Month 3, Month 6, compared to the baseline

  3. Serious adverse events related to EKOS or procedure

    All of SAE related to EKOS or procedure

    Time frame: After enrollment to end of study,through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2028, 20 months after the start.

Of 160 observational studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 105. This study's planned 20 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Feb 11, 2025
StartActual
Sep 30, 2026was Aug 2026
Primary completionEst.
May 30, 2028
CompletionEst.
May 30, 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 30, 2026→Sep 30, 2026
Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    Start date Aug 30, 2026→Sep 30, 2026
    + 1 other change: verification date
  2. Sep 29, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06819865
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Sep 30, 2026
Primary completion
May 30, 2028 (estimated)
Completion
May 30, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Guangqi Chang, Doctor
Contact
changgq@mail.sysu.edu.cn
020-87755766
Cheng Hong, Doctor
Contact
gyfyyhc@126.com
020-81568636
Cheng Hong, Doctor
principal investigator · The First Affiliated Hospital of Guangzhou Medical University
Guangqi Chang, Doctor
principal investigator · First Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion